Loading
Life sciences · Journal article
Langenbeck S Archives of Surgery · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background The role of primary tumor resection (PTR) in patients with colorectal cancer (CRC) and unresectable distant metastases remains controversial. While PTR may prevent tumor-related complications, it delays systemic therapy and carries surgical risks. This systematic review and meta-analysis synthesizes evidence from randomized controlled trials (RCTs) comparing PTR followed by systemic therapy versus systemic therapy alone. Methods This systematic review was registered with PROSPERO (registration number CRD42024533819) and conducted according to PRISMA 2020 guidelines. We searched PubMed, Cochrane Library, CINAHL, Scopus, and Google Scholar on August 6, 2024 for RCTs comparing PTR plus systemic therapy versus systemic therapy alone in patients with CRC and unresectable metastases. Study selection and data extraction were performed independently by two reviewers. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. Meta-analyses were performed using random-effects models for overall survival (OS), mortality, and delayed PTR rates. Heterogeneity was assessed using I² statistics. Results Five RCTs comprising 1,122 patients were included. Meta-analysis of four studies ( n = 1,074) showed no significant difference in OS between PTR plus systemic therapy and systemic therapy alone (pooled HR 0.87, 95% CI 0.69–1.10, p = 0.15, I²=44%). Mortality analysis of three studies ( n = 409) demonstrated a non-significant trend toward higher mortality with PTR (pooled RR 1.78, 95% CI 0.67–4.73, I²=36%). Delayed PTR in the chemotherapy-alone arm occurred in 8% of patients (95% CI 3–18%, I²=79%). Conclusions Current evidence from RCTs does not support routine PTR in asymptomatic or minimally symptomatic patients with CRC and unresectable metastases. Systemic therapy alone appears to have acceptable rates of tumor-related complications.